Omkar Speciality Chemicals exits CIRP: FY26 losses

NCLT approval marks the formal exit from CIRP

Omkar Speciality Chemicals Limited has officially transitioned out of the Corporate Insolvency Resolution Process (CIRP) after the National Company Law Tribunal (NCLT) approved its resolution plan on July 31, 2025. The company’s subsequent disclosures focus on the period after this approval and the shift to a new management and oversight framework. For shareholders, the key takeaway has been that debt has reduced post-resolution, but operations have not yet translated into revenue. The company has reported nil revenue from operations for the first three quarters of FY 2025-26, while losses continued in each quarter. These results also sit alongside auditor commentary that draws attention to going-concern considerations given a negative net worth.

What the company reported for Q1 to Q3 FY26

Omkar Speciality Chemicals announced unaudited financial results for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025. Across Q1, Q2, and Q3 of FY26, revenue from operations was reported at ₹0 crore. Net profit or loss for the three quarters was a loss of ₹0.41 crore in Q1, ₹0.52 crore in Q2, and ₹0.33 crore in Q3. The company also separately highlighted that Q3 net loss was ₹32.84 lakhs, which is approximately ₹0.33 crore, consistent with the quarterly loss figure.

Monitoring Committee actions and the May 27, 2026 meeting

The company’s Monitoring Committee is central to post-resolution oversight. Omkar Speciality Chemicals stated that its Monitoring Committee would meet on May 27, 2026, to approve unaudited financials for the quarters ended June, September, and December 2025. The disclosures also state that the Monitoring Committee approved unaudited financial results for Q1, Q2, and Q3 FY26. Separately, the information provided also refers to the latest board meeting taking place on May 27, 2026, for the purpose of “Audited Results.” These references indicate that May 27, 2026 was a key governance date in the company’s post-CIRP reporting calendar, as described in the provided material.

Management and governance changes after resolution

Post the NCLT-approved resolution plan, Omkar Speciality Chemicals disclosed key appointments. Mr. Dipak Kumar Shaw was appointed as Chief Executive Officer (CEO). Mr. Ruhini Kumar Chakraborty was appointed as an Independent Director. The company also appointed R. R. Tibrewala & Co. as the Statutory Auditor for FY 2025-26. The appointment was described as filling a casual vacancy and as part of formalising governance after CIRP.

Auditor observations and the going-concern emphasis

The provided material notes an auditor’s qualified conclusion focused on the going concern basis, particularly in the context of negative net worth. While the detailed qualification wording is not included here, the reference is important because it frames how investors may interpret near-term financials when revenue is nil and losses persist. In addition, the material includes an excerpt stating that audited financial statements (including the balance sheet, profit and loss, changes in equity, and cash flows) present a “true and fair view” in conformity with Ind AS, and that there was “no key audit matter to be reported” in that excerpt. Taken together, the disclosures show the company is publishing regular financial information post-resolution while also drawing attention to balance sheet constraints.

Snapshot of key reported numbers

The company’s unaudited results for Q1 to Q3 FY26 highlight the immediate post-resolution operating picture: no operational revenue and quarterly losses.

Share price reference and listed identity

Omkar Speciality Chemicals is referenced as (NSE: OMKARCHEM) in the provided material. The share price is stated at ₹3.6 as of June 4, 2026. This price point is presented alongside the company’s post-CIRP developments and quarterly reporting updates.

Q4 FY26 results schedule and what is being discussed

The company is preparing to announce Q4 FY26 financial results for the quarter ended March 31, 2026. The provided material states that Q4 FY26 results are scheduled for May 2026 (Expected). It also states the board of directors will meet on that date to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation.

Alongside the scheduling references, the material includes analyst estimates for Q4 FY26. Those estimates indicate expected revenue of ₹120–140 crore, PAT of ₹6–10 crore, and projected EBITDA margin of 12–15%. These figures are presented as analyst expectations, not as company-reported results.

Why the FY26 Q1 to Q3 numbers matter after CIRP

The post-resolution phase is typically judged on the speed of operational normalisation and the stability of governance and reporting. In Omkar Speciality Chemicals’ case, the disclosed FY26 Q1 to Q3 numbers underscore that operations, at least in reported revenue terms, remain inactive or not yet reflected in the financials. At the same time, the company has disclosed leadership and audit appointments, and it has continued to publish quarterly financial information.

The auditor reference to going-concern assumptions amid negative net worth adds another layer for investors to track, especially when revenue from operations remains at ₹0 crore across multiple quarters. The next major datapoint, as described in the material, is the Q4 FY26 reporting cycle expected in May 2026, where audited numbers for the quarter ended March 31, 2026 are expected to be taken up.

Conclusion

Omkar Speciality Chemicals’ exit from CIRP following the July 31, 2025 NCLT approval has been followed by governance appointments and unaudited Q1 to Q3 FY26 results showing ₹0 crore revenue and continuing quarterly losses. The next scheduled milestone referenced is the Q4 FY26 result process in May 2026 (Expected), including a board meeting to approve audited statements for the quarter ended March 31, 2026 and to consider a final dividend recommendation.